Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

New York, New York 10021


Purpose:

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Combining an immune adjuvant with a vaccine may cause a stronger immune response and kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of immune adjuvant when given together with vaccine therapy and to see how well they work in treating patients with stage IIB, stage IIC, stage III, or stage IV melanoma.


Study summary:

OBJECTIVES: Primary - Determine the maximum tolerated dose and recommended dose of sargramostim (GM-CSF) plasmid DNA adjuvant with a multi-epitope peptide vaccine comprising tyrosinase peptide and gp100 antigen in patients with stage IIB, IIC, III, or IV melanoma who are HLA-A2-positive. - Determine the safety of this regimen in these patients. - Determine the pharmacokinetics of this regimen in these patients. - Determine the dose-limiting toxic effects of this regimen in these patients. - Determine the immunogenicity of this regimen in these patients. Secondary - Determine any anti-tumor response in patients treated with this regimen. OUTLINE: This is a phase I, pilot, dose-escalation study of sargramostim (GM-CSF) plasmid DNA adjuvant followed by a phase II, pilot study. - Phase I: Patients receive GM-CSF plasmid DNA adjuvant subcutaneously (SC) on day 1 and a vaccine comprising tyrosinase peptide and gp100 antigen SC on day 5. Treatment repeats every 28 days for a total of 3 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of GM-CSF plasmid DNA adjuvant until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. - Phase II: Patients receive vaccination as in phase I at the MTD. After completion of study, patients are followed up for 1 year. PROJECTED ACCRUAL: A total of 3-27 patients (3-18 for phase I and 9 for phase II) will be accrued for this study within 2-14 months.


Criteria:

DISEASE CHARACTERISTICS: - Histologically confirmed malignant melanoma - Stage IIB, IIC, III, or IV disease - Patients with resectable disease must have undergone surgical resection before study entry - Patients free of disease after surgical resection are eligible up to 6 months after resection - HLA-A0201 positive - No detectable brain metastases by brain MRI or CT scan PATIENT CHARACTERISTICS: Age - Any age if weight > 25 kg (55 lb) Performance status - Karnofsky 80-100% Life expectancy - Not specified Hematopoietic - WBC ≥ 3,000/mm^3 - Platelet count ≥ 100,000/mm^3 - No active bleeding Hepatic - Lactic dehydrogenase ≤ 2 times upper limit of normal (ULN) - Albumin ≥ 3.5 mg/dL - AST ≤ 2 times ULN Renal - Creatinine ≤ 2 mg/dL - No prior creatinine > 2 mg/dL Other - Must weigh ≥ 25 kg - No medical condition that would preclude study participation (e.g., active autoimmune disease or immunodeficiency) - No pre-existing retinal or choroidal eye disease - No inflammation of the eyes - No serious underlying medical conditions - No active infection requiring antimicrobial drugs - Not pregnant or nursing - At least 3 months post-partum - Negative pregnancy test - Fertile patients must use effective barrier contraception during and for 3 months after study participation PRIOR CONCURRENT THERAPY: Biologic therapy - More than 4 weeks since prior immunotherapy - No prior vaccines containing tyrosinase peptide or gp100 antigen or peptides derived from tyrosinase peptide or gp100 antigen - No other concurrent immunotherapy Chemotherapy - More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) - No concurrent chemotherapy Endocrine therapy - More than 6 weeks since prior systemic corticosteroids - Inhaled or nasal steroids allowed Radiotherapy - More than 4 weeks since prior radiotherapy - No concurrent radiotherapy Surgery - See Disease Characteristics - Recovered from prior surgery Other - Recovered from all prior therapy - No concurrent medication that would preclude study participation


NCT ID:

NCT00085137


Primary Contact:

Principal Investigator
Miguel-Angel Perales, MD
Memorial Sloan-Kettering Cancer Center


Backup Contact:

N/A


Location Contact:

New York, New York 10021
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: June 25, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.